XOMA Corporation (XOMA)

[dav1234]

investor conference tomorrow, 10:25 am
might not amount to much but any investor interested in XOMA will want to know about the GS loan issues and why its not done yet.( it's been about a month since CEO ENGLE stated that GS loan should be resolved)

CEO could surprise everyone with some news timed to the conference or it could just be more of the same .

i do believe that the company wants the stock price higher so i would expect some positive progress to be announced ( could be Higher than expected CIMZIA royalties, GS loan resolution or XOMA O52 partner progress or even additional gov't payments for vaccine work)

conference is not really fluff, ALAN GREENSPAN is the keynote speaker and its in New York so we could expect serious investors to be watching.http://www.rodm.com/conferences?id=30

http://www.xoma.com/company/news-events/press-releases/index.cfm?releaseID=407136
BERKELEY, Calif., Sept. 4, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a
leader in the discovery and development of antibody therapeutics, announced that
Steven Engle, Chairman and Chief Executive Officer, is scheduled to present at
the following conferences in September 2009:

Rodman &; Renshaw 11th Annual Healthcare Conference, New York City: September 10,
10:25 am EDT

BioCentury NewsMakers in the Biotech Industry Conference, New York City:
September 16, 9:25 am EDT

Live and archived webcasts of these presentations will be available via the
Investors tab of the XOMA website, www.xoma.com.

About XOMA

XOMA discovers, develops and manufactures antibody therapeutics designed to
treat inflammatory, autoimmune, infectious and oncological diseases. The
company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta
antibody entering Phase 2 development, and XOMA 3AB, a biodefense anti-botulism
antibody candidate.

XOMA has world-leading capabilities in antibody engineering and formulation,
including a unique collection of antibody phage display libraries and expertise
in the rapid construction of large novel libraries. Access to multiple libraries
may offer a number of benefits to XOMA, its partners and licensees because it
enables the use of libraries best suited to the needs of a particular discovery
project. This increases the probability of technical and business success in
finding rare and unique functional antibodies directed to targets of interest.

XOMA's proprietary technology platform also includes Targeted Affinity
Enhancement(tm) for rapid, focused antibody affinity maturation, Human
Engineering(tm) for antibody humanization and its widely-licensed bacterial cell
expression and manufacturing technologies which have been licensed to more than
50 companies.

XOMA's multiple revenue streams result from the licensing of its antibody
technologies, product royalties, development collaborations and biodefense
contracts. XOMA's technologies team have contributed to the success of marketed
antibody products, including LUCENTIS(r) (ranibizumab injection) for wet
age-related macular degeneration and CIMZIA(r) (certolizumab pegol) for
rheumatoid arthritis and Crohn's disease.

In addition to developing its own products, XOMA develops products with premier
pharmaceutical companies including Schering-Plough Research Institute and Takeda
Pharmaceutical Company Limited. XOMA has a fully integrated product development
infrastructure, extending from pre-clinical science to approval, and a team of
approximately 190 employees at its Berkeley, CA location. For more information,
please visit href="http://www.xoma.com." rel="nofollow" target="_blank">http://www.xoma.com.>